All In Biotech

Drug Trial Radar · NCT07046806

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

Oral Deucrictibant for the Prophylactic and Acute Treatment in Patients With Bradykinin Mediated Angioedema With Normal C1 Inhibitor (BK-AE-nC1INH)

Last checked: Nov 19, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Mar 10, 2025

Primary completion

Apr 1, 2026

Study completion Apr 1, 2026

Sponsor

Lead sponsor
Institute for Asthma and AllergyResearch network
Sponsor type
Research network
First posted
Jul 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.

Conditions

  • Hereditary Angioedema (HAE)
  • Angioedema
  • Bradykinin-mediated Angioedema
  • C1 Inhibitor Deficiency

Interventions

  • Deucrictibant XR tabletDrug

    Deucrictibant 40 mg XR tablet for prophylaxis

  • Placebo comparator to XR tabletDrug

    Placebo comparator to deucrictibant 40 mg XR tablet, prophylaxis

  • Deucrictibant 20 mg capsuleDrug

    Deucrictibant active drug for on-demand treatment of angioedma attacks

  • Placebo comparator to 20 mg capsuleDrug

    Placebo comparator to Deucrictibant 20 mg capsule for on-demand treatment of angioedema attacks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part-1: Incidence and quality of HAE attacks comparing active versus placebo arms.Time frame: 24 weeks
  2. Part-2: Efficacy of active on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacksTime frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute For Asthma & Allergy

    Wheaton, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.